2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148380A
    Mal-PEG8-Phe-Lys-PAB-Exatecan TFA
    		98.44%
    Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631).
    Mal-PEG8-Phe-Lys-PAB-Exatecan TFA
  • HY-148346A
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA
    		98.20%
    STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer.
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA
  • HY-153345
    Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br
    		99.67%
    Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br is an Drug-linker conjugates for ADC that can be used as a reaction reagent for the synthesis of anti-CD40 antibody agent conjugates (ADCs).
    Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br
  • HY-19813A
    mDPR-Val-Cit-PAB-MMAE TFA
    		99.51%
    mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition[1].
    mDPR-Val-Cit-PAB-MMAE TFA
  • HY-133492
    DBCO-PEG4-MMAF
    		99.31%
    DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-MMAF
  • HY-101982A
    (Rac)-Lys-SMCC-DM1
    		98.18%
    (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1 (HY-101982). Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1.
    (Rac)-Lys-SMCC-DM1
  • HY-104025
    SPB
    		98.20%
    SPB is a agent-linker conjugate for ADC with potent anti-inflammatory activity by using Xanthotoxol, linked via the ADC linker.
    SPB
  • HY-128979
    Deruxtecan analog 2
    		99.56%
    Deruxtecan analog 2 (example 9 P3) is a Deruxtecan (HY-13631E) analog. Deruxtecan analog 2 is a agent-linker conjugate composed of Camptothecin (HY-16560) and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
    Deruxtecan analog 2
  • HY-19812
    Acetylene-linker-Val-Cit-PABC-MMAE
    Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-linker-Val-Cit-PABC-MMAE
  • HY-126491
    SPP-DM1
    SPP-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker SPP.
    SPP-DM1
  • HY-148875
    Py-MAA-Val-Cit-PAB-MMAE
    		99.78%
    Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors.
    Py-MAA-Val-Cit-PAB-MMAE
  • HY-15742
    Vc-MMAD
    		99.96%
    Vc-MMAD consists the ADCs linker (Val-Cit) and potent tubulin inhibitor (MMAD). Vc-MMAD is a agent-linker conjugate for ADC.
    Vc-MMAD
  • HY-111554
    AcLys-PABC-VC-Aur0101
    		98.49%
    AcLys-PABC-VC-Aur0101 is a agent-linker conjugate for ADC (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC.
    AcLys-PABC-VC-Aur0101
  • HY-157465
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM
    		99.84%
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM is a drug-linker conjugate for ADC by using the DNA minor-groove alkylator Duocarmycin DM (HY-130978), linked via MA-PEG4-vc-PAB-DMEA (HY-126668).
    MA-PEG4-VC-PAB-DMEA-duocarmycin DM
  • HY-155870A
    DL-01 formic
    DL-01 formic is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01 formic
  • HY-148245
    OH-Glu-Val-Cit-PAB-MMAE
    		99.92%
    OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    OH-Glu-Val-Cit-PAB-MMAE
  • HY-136286
    MC-DM1
    MC-DM1 is a agent-linker conjugate composed of a potent microtubule-disrupting agent DM1 and a linker MC to make antibody agent conjugate (ADC).
    MC-DM1
  • HY-153601
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A is a Spliceostatin (HY-16466) analog, and a drug-linker conjugates for ADC, consisting of ADC Cytotoxin Thailanstatin A (HY-129589) and cleavable ADC linker (MC-vc-PAB). MC-VC-PAB-Cyclohexanediamine-Thailanstatin A can be used for ADC synthesis.
    MC-VC-PAB-Cyclohexanediamine-Thailanstatin A
  • HY-126691
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682, a agent-linker conjugate for ADC, consists the ADC linker DBCO-PEG4-VC-PAB and a potent ADC cytotoxin DMEA-PNU-159682. DMEA-PNU-159682 includes metabolites of nemorubicin (MMDX) from liver microsomes and ADC cytotoxin PNU-159682. DBCO-PEG4-VC-PAB-DMEA-PNU-159682 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-VC-PAB-DMEA-PNU-159682
  • HY-128897
    MC-VC-PABC-DNA31
    		98.71%
    MC-VC-PABC-DNA31 is a agent-linker conjugate for ADC with potent antitumor activity by using DNA31 (a potent RNA polymerase inhibitor), linked via the ADC linker MC-VC-PABC.
    MC-VC-PABC-DNA31
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.